Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07156526 · ClinicalTrials.gov registry record · NA
Impact of Two Iron Formulations on Iron Biomarkers and Quality of Life
A NA study, sponsored by Qualia Life Sciences.
- Not yet
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT07156526: Clinical Trial NA study, sponsored by Qualia Life Sciences.
NCT07156526 is a NA study that has not yet begun recruiting, run by Qualia Life Sciences. The registered enrollment target is 40 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07156526, a NA study, has not yet begun recruiting, sponsored by Qualia Life Sciences.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
This randomized, double-blind parallel pilot study will evaluate the safety and efficacy of two Qualia Iron formulations versus placebo in approximately 40 healthy adults (aged 18+) over a 56-day period. Approximately 40 participants will be randomized to three study arms: Qualia Iron Version 1, 2, (n=15 each) or a Placebo (n=10). Each participant will take one or two capsules once daily in the morning, with or without food. The supplementation regimen is a 5 days on, 2 days off protocol, and goes for 56 days (8 weeks). The primary outcomes of this study are to assess between-group changes in iron status biomarkers. Secondary outcomes include within-group changes in iron status biomarkers, safety and tolerability as measured by a custom Safety and Tolerability survey, and RAND SF-36 quality of life scores.
Primary Outcome
Between-groups changes in ferritin levels (ng/mL) will be assessed.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Qualia Iron Version A
- DIETARY_SUPPLEMENT Qualia Iron Version B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-09-10 |
| Est. Completion | 2025-11-15 |
| Phase | NA |
What is known before NCT07156526 opens enrollment
NCT07156526 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07156526 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07156526 about?
NCT07156526 is a clinical study titled "Impact of Two Iron Formulations on Iron Biomarkers and Quality of Life". This randomized, double-blind parallel pilot study will evaluate the safety and efficacy of two Qualia Iron formulations versus placebo in approximately 40 healthy adults (aged 18+) over a 56-day period. Approximately 40 participants will be randomized to three study arms: Qualia Iron Version 1, 2, ...
What is the current status of trial NCT07156526?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-09-10. Estimated completion is 2025-11-15.
What interventions are being tested in trial NCT07156526?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Qualia Iron Version A (DIETARY_SUPPLEMENT), Qualia Iron Version B (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07156526?
This trial is sponsored by Qualia Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07156526's enrollment target sits among peer trials
40 1447th of 2000 higher than 465 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI